 |
|
EU research fights killer viruses' stubborn resistance to drugs
June 29, 2004Viruses' growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences. The EU is therefore contributing EUR9 million to the "Vigilance against Viral Resistance" (VIRGIL) project, to be launched today in Lyon (France). It will start by addressing drug resistance in viral hepatitis and influenza, but will broaden its scope to other viruses.
The network will be based on research and technological platforms to monitor existing, and anticipate future, drug resistance. One platform will monitor, test and improve the management of antiviral drug resistance in patients while another will show how resistance occurs and help understand patient-related (immune/genetic) factors causing viral resistance. Other platforms for drugs and pharmacology and for innovation and technology will allow anticipation of ways to rapidly overcome drug resistance. Finally, a societal impact platform will assess the network's benefit for medicine and patients' quality of life. VIRGIL, coordinated by Lyon's INSERM research centre, will gather 55 key European field experts from 12 countries, including 7 partners from industry.
"The heavy use of antibiotics, particularly in hospitals, hastens mutations in bacteria which bring about drug resistance. The same happens in viruses when antiviral drugs are used extensively," European Research Commissioner Philippe Busquin said. "VIRGIL complements a EUR30 million EU research investment into antimicrobial drug resistance over the past two years to address this growing problem. Through collaboration between European academic researchers, the pharmaceutical industry, clinicians and public health authorities the network will help overcome problems associated with viral drug resistance to help save lives."
Killer diseases: on the rampage?
Viral hepatitis causes chronic liver disease, including cirrhosis and liver cancer. Although a safe and efficient vaccine does exist for hepatitis B, over 350 million people around the world are now chronically infected with this virus. For hepatitis C, no vaccine exists and over 1% of Europeans are carriers. Intensive clinical use of the few available drugs has led to rapidly emerging drug resistance for some viruses so that these drugs are no longer efficient.
Yearly epidemics of new flu strains infect 5-15% of the world population with up to 500.000 deaths. Genetic changes in the influenza virus may lead to severe epidemics of global dimension (pandemics), such as the Spanish flu of 1918 that killed over 40 million people.
Experts now fear another pandemic may arise shortly with unforeseeable consequences. Access to efficient drugs will be essential in such a catastrophic scenario. Again, the virus is likely to develop drug resistance.
EU research saves lives and money
The VIRGIL network will be able to rapidly and reliably determine resistance to new drugs and the drug susceptibility of emerging viral strains based on new treatments. The network aims to link up with the antiviral drug producing pharmaceutical industry in a cost-effective partnership that will help to ensure longer access to treatment and cure for the patients. This will help contain the socio-economic burden of viral resistance, now representing a major health problem with higher health care and drug development costs.
European Commission, Research Directorate
Drug Resistance Current Events and Drug Resistance News RSSProlonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV
Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report.
Case Western Reserve professor helps control infectious diseases with models and math
Can an algebraic equation hold the secret to eradicating malaria or schistosomiasis? A Case Western Reserve University mathematics professor is utilizing the combination of algorithms and models in an effort to assist his medical colleagues in the fight against infectious diseases.
Not Just for Depression Anymore
Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer. But can this common anti-depressant help to fight cancer itself?
Charting HIV's rapidly changing journey in the body
HIV is so deadly largely because it evolves so rapidly. With a single virus as the origin of an infection, most patients will quickly come to harbor thousands of different versions of HIV, all a little bit different and all competing with one another to most efficiently infect that person's cells.
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Markers of inflammation and blood-clotting tied to hazards of intermittent HIV treatment
Episodic treatment of HIV/AIDS with antiretroviral drugs increases the overall risk of death when compared with continuous antiretroviral treatment (ART), but the reasons why have been unknown.
Scientists decode genome of parasite that causes relapsing malaria
Scientists have deciphered the complete genetic sequence of the parasite Plasmodium vivax, the leading cause of relapsing malaria, and compared it with the genomes of other species of malaria parasites.
MU scientists 'see' how HIV matures into an infection
After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death.
More Drug Resistance Current Events and Drug Resistance News Articles
 | HIV-1 Resistance in Supervised Treatment Settings: Predictors and Consequences of Drug Resistance inPatients with Late Stage Human ImmunodeficiencyVirus -1 disease in Supervised Treatment Settings by Delivette Castor, Donald R. Hoover, Scott M. Hammer, David Vlahov Positive treatment outcomes for patients with HumanImmunodeficiency Virus-1 (HIV-1) disease may becompromised by the selection of HIV-1 drug resistantmutants (HIVDRM), particularly in marginalizedpopulations where fragmented care is prevalent.Adherence as an important co-factor in selectingHIVDRMs has been controversial. Thus, understandingthe causes and effects of HIVDRMs in the contextadherence... |
 | Antimicrobial Resistance in Bacteria of Animal Origin Antimicrobial Resistance in Bacteria of Animal Origin comprehensively examines the current research on antimicrobial resistance in the main veterinary and zoonotic pathogens, including resistance to disinfectants and metals used in agriculture. Providing a broad overview from a global perspective, this new volume is an important reference for students, researchers, public health experts,... |
 | Cancer Drug Resistance (Cancer Drug Discovery and Development) Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug... |
| The Mechanism and New Approach on Drug Resistance of Cancer Cells: Proceedings of the International Symposium on the Mechanism and New Approach on D (International Congress Series) by Tamotsu Miyazaki, Fumimaro Takaku | |
 | Cancer Drug Resistance Research Perspectives One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in... |
 | Adaptation or selection? Old issues and new stakes in the postwar debates over bacterial drug resistance [An article from: Studies in History and Philosophy of Biol & Biomed Sci] by A.N.H. Creager This digital document is a journal article from Studies in History and Philosophy of Biol & Biomed Sci, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: The 1940s and 1950s were marked by intense debates over the origin of drug resistance in... |
 | Drug Resistance in Cancer: Mechanisms and Models by James H. Goldie, Andrew J. Coldman Drug resistance in cancer, whereby a portion of cancer cells evades chemotherapy, poses a profound and continuing challenge for the effective treatment of cancer. The principles underlying the biological mechanisms behind this phenomenon are clearly explained in this volume. A deeper understanding of drug resistance requires a quantitative appreciation of the dynamic forces that shape tumor... |
 | Antiviral Drug Resistance The study of antiviral drug resistance has provided important insights into the structure of virus enzymes, the functions of certain genes, mechanisms of action of antiviral drugs, the design of new antiviral compounds and the pathogenesis of viral diseases. The emergence of resistant strains must be explored at all stages of drug development: during the preclinical evaluation of candidate... |
| Drug resistance soars among nosocomial gram-negative bacteria.(Infectious Diseases): An article from: Internal Medicine News by Mitchel L. Zoler This digital document is an article from Internal Medicine News, published by International Medical News Group on June 15, 2004. The length of the article is 746 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| HHMI Identifies Cause of Drug-resistance.: An article from: Analytic Separations News This digital document is an article from Analytic Separations News, published by Business Communications Company, Inc. on February 1, 2004. The length of the article is 951 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... |
| © 2009 BrightSurf.com |